Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.

@article{Kelloff2006ProgressIC,
  title={Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.},
  author={Gary j. Kelloff and Scott Michael Lippman and Andrew J. Dannenberg and Caroline C. Sigman and Homer L. Pearce and Brian J. Reid and Eva Szab{\'o} and Virgil Craig Jordan and Margaret R. Spitz and Gordon B. Mills and Vassiliki A. Papadimitrakopoulou and Reuben Lotan and Bharat Bhushan Aggarwal and Robert S. Bresalier and Jeri Kim and Banu K. Arun and Karen H. Lu and Melanie E Thomas and Helen E Rhodes and Molly A. Brewer and Michele Follen and Dong M Shin and Howard L. Parnes and Jill M. Siegfried and Alison A. Evans and William J. Blot and Wong-Ho Chow and Patricia L. Blount and Carlo C. Maley and Kenneth K. Wang and Stephen Lam and J Jack Lee and Steven Dubinett and Paul F. Engstrom and Frank L. Meyskens and Joyce O'Shaughnessy and Ernest T. Hawk and Bernard Levin and William Andrew Nelson and Waun Ki Hong},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2006},
  volume={12 12},
  pages={3661-97}
}
This article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point… CONTINUE READING